title: Hormone substitution in male hypogonadism.
abstract: Male hypogonadism is characterised by androgen deficiency and infertility. Hypogonadism can be caused by disorders at the hypothalamic or pituitary level (hypogonadotropic forms) or by testicular dysfunction (hypergonadotropic forms). Testosterone substitution is necessary in all hypogonadal patients, because androgen deficiency causes slight anemia, changes in coagulation parameters, decreased bone density, muscle atrophy, regression of sexual function and alterations in mood and cognitive abilities. Androgen replacement comprises injectable forms of testosterone as well as implants, transdermal systems, sublingual, buccal and oral preparations. Transdermal systems provide the pharmacokinetic modality closest to natural diurnal variations in testosterone levels. New injectable forms of testosterone are currently under clinical evaluation (testosterone undecanoate, testosterone buciclate), allowing extended injection intervals. If patients with hypogonadotropic hypogonadism wish to father a child, spermatogenesis can be initiated and maintained by gonadotropin therapy (conventionally in the form of human chorionic gonadotropin (hCG) and human menopausal gonadotropin (hMG) or, more recently, purified or recombinant follicle stimulating hormone (FSH)). Apart from this option, patients with disorders at the hypothalamic level can be stimulated with pulsatile gonadotropin-releasing hormone (GnRH). Both treatment modalities have to be administered on average for 7-10 months until pregnancy is achieved. In individual cases, treatment may be necessary for up to 46 months. Testosterone treatment is interrupted for the time of GnRH of gonadotropin therapy, but resumed after cessation of this therapy.
authors.affiliation: Institute of Reproductive Medicine of the University, Domagkstr. 11, D-48149, Münster, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Zitzmann
authors.forename: E
authors.initials: E
authors.lastname: Nieschlag
mesh_terms: D000818:Animals; D000075202:Contraindications; D004333:Drug Administration Routes; D016503:Drug Delivery Systems; D012739:Gonadal Steroid Hormones / Q000008:administration & dosage / Q000172:deficiency; D006062:Gonadotropins / Q000008:administration & dosage / Q000627:therapeutic use; D020249:Hormone Replacement Therapy; D006801:Humans; D007006:Hypogonadism / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D007248:Infertility, Male / Q000188:drug therapy; D008297:Male; D013739:Testosterone / Q000008:administration & dosage* / Q000172:deficiency
chemical_list: D012739:Gonadal Steroid Hormones; D006062:Gonadotropins; D013739:Testosterone